BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

166 related articles for article (PubMed ID: 27019002)

  • 1. LSD1 inhibitors: a patent review (2010-2015).
    Stazi G; Zwergel C; Valente S; Mai A
    Expert Opin Ther Pat; 2016 May; 26(5):565-80. PubMed ID: 27019002
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Drug Design Concepts for LSD1-Selective Inhibitors.
    Ota Y; Suzuki T
    Chem Rec; 2018 Dec; 18(12):1782-1791. PubMed ID: 30277644
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Small-molecule inhibitors of histone deacetylase for the treatment of cancer and non-cancer diseases: a patent review (2011 - 2013).
    Valente S; Mai A
    Expert Opin Ther Pat; 2014 Apr; 24(4):401-15. PubMed ID: 24397271
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Identification of Novel Selective Lysine-Specific Demethylase 1 (LSD1) Inhibitors Using a Pharmacophore-Based Virtual Screening Combined with Docking.
    Zhou C; Kang D; Xu Y; Zhang L; Zha X
    Chem Biol Drug Des; 2015 Jun; 85(6):659-71. PubMed ID: 25346381
    [TBL] [Abstract][Full Text] [Related]  

  • 5. TCPs: privileged scaffolds for identifying potent LSD1 inhibitors for cancer therapy.
    Zheng YC; Yu B; Chen ZS; Liu Y; Liu HM
    Epigenomics; 2016 May; 8(5):651-66. PubMed ID: 27102879
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Advances toward LSD1 inhibitors for cancer therapy.
    Fu X; Zhang P; Yu B
    Future Med Chem; 2017 Jul; 9(11):1227-1242. PubMed ID: 28722477
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Inhibitors of LSD1 as a potential therapy for acute myeloid leukemia.
    Przespolewski A; Wang ES
    Expert Opin Investig Drugs; 2016 Jul; 25(7):771-80. PubMed ID: 27077938
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Trends of LSD1 inhibitors in viral infections.
    Zwergel C; Stazi G; Mai A; Valente S
    Future Med Chem; 2018 May; 10(10):1133-1136. PubMed ID: 29787289
    [No Abstract]   [Full Text] [Related]  

  • 9. LSD1 inhibition: a therapeutic strategy in cancer?
    Lynch JT; Harris WJ; Somervaille TC
    Expert Opin Ther Targets; 2012 Dec; 16(12):1239-49. PubMed ID: 22957941
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Discovery of resveratrol derivatives as novel LSD1 inhibitors: Design, synthesis and their biological evaluation.
    Duan YC; Guan YY; Zhai XY; Ding LN; Qin WP; Shen DD; Liu XQ; Sun XD; Zheng YC; Liu HM
    Eur J Med Chem; 2017 Jan; 126():246-258. PubMed ID: 27888721
    [TBL] [Abstract][Full Text] [Related]  

  • 11. An Update of Lysine Specific Demethylase 1 Inhibitor: A Patent Review (2016-2020).
    Zheng YC; Liu YJ; Gao Y; Wang B; Liu HM
    Recent Pat Anticancer Drug Discov; 2022; 17(1):9-25. PubMed ID: 34323202
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Structure-based design and discovery of potent and selective lysine-specific demethylase 1 (LSD1) inhibitors.
    Nie Z; Shi L; Lai C; Severin C; Xu J; Del Rosario JR; Stansfield RK; Cho RW; Kanouni T; Veal JM; Stafford JA; Chen YK
    Bioorg Med Chem Lett; 2019 Jan; 29(1):103-106. PubMed ID: 30409536
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Emerging approaches for histone deacetylase inhibitor drug discovery.
    Zwergel C; Valente S; Jacob C; Mai A
    Expert Opin Drug Discov; 2015 Jun; 10(6):599-613. PubMed ID: 25895649
    [TBL] [Abstract][Full Text] [Related]  

  • 14. EZH2 inhibitors: a patent review (2014-2016).
    Stazi G; Zwergel C; Mai A; Valente S
    Expert Opin Ther Pat; 2017 Jul; 27(7):797-813. PubMed ID: 28394193
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Research progress of LSD1-based dual-target agents for cancer therapy.
    Yang X
    Bioorg Med Chem; 2024 Mar; 101():117651. PubMed ID: 38401457
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Medicinal chemistry insights in the discovery of novel LSD1 inhibitors.
    Wang X; Huang B; Suzuki T; Liu X; Zhan P
    Epigenomics; 2015; 7(8):1379-96. PubMed ID: 26646727
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Design, synthesis and biological activity of 3-oxoamino-benzenesulfonamides as selective and reversible LSD1 inhibitors.
    Xi J; Xu S; Wu L; Ma T; Liu R; Liu YC; Deng D; Gu Y; Zhou J; Lan F; Zha X
    Bioorg Chem; 2017 Jun; 72():182-189. PubMed ID: 28460360
    [TBL] [Abstract][Full Text] [Related]  

  • 18. LSD1 inhibitors for anticancer therapy: a patent review (2017-present).
    Lv YX; Tian S; Zhang ZD; Feng T; Li HQ
    Expert Opin Ther Pat; 2022 Sep; 32(9):1027-1042. PubMed ID: 35914778
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Tying up tranylcypromine: Novel selective histone lysine specific demethylase 1 (LSD1) inhibitors.
    Ji YY; Lin SD; Wang YJ; Su MB; Zhang W; Gunosewoyo H; Yang F; Li J; Tang J; Zhou YB; Yu LF
    Eur J Med Chem; 2017 Dec; 141():101-112. PubMed ID: 29031059
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Design, synthesis and evaluation of γ-turn mimetics as LSD1-selective inhibitors.
    Ota Y; Miyamura S; Araki M; Itoh Y; Yasuda S; Masuda M; Taniguchi T; Sowa Y; Sakai T; Itami K; Yamaguchi J; Suzuki T
    Bioorg Med Chem; 2018 Feb; 26(3):775-785. PubMed ID: 29331452
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.